Posted inClinical Updates Diabetes & Endocrinology
Acmopatide Shows Promising Glycemic and Weight Control in Overweight Adults with Type 1 Diabetes: Phase 2 Trial Results
Acmopatide, a novel biased GLP-1/GIP receptor agonist, improves glycemic control and reduces body weight without severe adverse events in overweight adults with type 1 diabetes, based on a 16-week phase 2 randomized trial.